WallStreetZenWallStreetZen

NASDAQ: NKTX
Nkarta Inc Stock

$6.47+0.26 (+4.19%)
Updated Jul 22, 2024
NKTX Price
$6.47
Fair Value Price
-$1.17
Market Cap
$455.93M
52 Week Low
$1.28
52 Week High
$16.24
P/E
-2.75x
P/B
0.96x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$116.20M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.22
Operating Cash Flow
-$94M
Beta
1.58
Next Earnings
Aug 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A

NKTX Overview

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NKTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

NKTX ($6.47) is overvalued by 653.45% relative to our estimate of its Fair Value price of -$1.17 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NKTX ($6.47) is not significantly undervalued (653.45%) relative to our estimate of its Fair Value price of -$1.17 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NKTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NKTX due diligence checks available for Premium users.

Be the first to know about important NKTX news, forecast changes, insider trades & much more!

NKTX News

Valuation

NKTX fair value

Fair Value of NKTX stock based on Discounted Cash Flow (DCF)
Price
$6.47
Fair Value
-$1.17
Undervalued by
653.45%
NKTX ($6.47) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NKTX ($6.47) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NKTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

NKTX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-2.75x
Industry
-27.86x
Market
29.85x

NKTX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.96x
Industry
6.3x
NKTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

NKTX's financial health

Profit margin

Revenue
$0.0
Net Income
-$29.5M
Profit Margin
0%
NKTX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$576.9M
Liabilities
$103.3M
Debt to equity
0.22
NKTX's short-term assets ($442.78M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NKTX's short-term assets ($442.78M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NKTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$28.5M
Investing
$21.5M
Financing
$226.3M
NKTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

NKTX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
NKTX$455.93M+4.19%-2.75x0.96x
AURA$453.32M+5.54%-4.92x2.17x
ALT$451.65M+1.43%-3.96x2.61x
KRRO$448.63M+6.17%-1.73x2.96x
ABSI$463.64M+3.27%-3.53x1.93x

Nkarta Stock FAQ

What is Nkarta's quote symbol?

(NASDAQ: NKTX) Nkarta trades on the NASDAQ under the ticker symbol NKTX. Nkarta stock quotes can also be displayed as NASDAQ: NKTX.

If you're new to stock investing, here's how to buy Nkarta stock.

What is the 52 week high and low for Nkarta (NASDAQ: NKTX)?

(NASDAQ: NKTX) Nkarta's 52-week high was $16.24, and its 52-week low was $1.28. It is currently -60.16% from its 52-week high and 405.47% from its 52-week low.

How much is Nkarta stock worth today?

(NASDAQ: NKTX) Nkarta currently has 70,467,620 outstanding shares. With Nkarta stock trading at $6.47 per share, the total value of Nkarta stock (market capitalization) is $455.93M.

Nkarta stock was originally listed at a price of $47.90 in Jul 10, 2020. If you had invested in Nkarta stock at $47.90, your return over the last 4 years would have been -86.49%, for an annualized return of -39.38% (not including any dividends or dividend reinvestments).

How much is Nkarta's stock price per share?

(NASDAQ: NKTX) Nkarta stock price per share is $6.47 today (as of Jul 22, 2024).

What is Nkarta's Market Cap?

(NASDAQ: NKTX) Nkarta's market cap is $455.93M, as of Jul 24, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Nkarta's market cap is calculated by multiplying NKTX's current stock price of $6.47 by NKTX's total outstanding shares of 70,467,620.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.